Stoboclo (Denosumab-Bmwo) for Osteoporosis

Overview
Stoboclo is approved by the U.S. Food and Drug Administration (FDA) for treatment for osteoporosis in postmenopausal women at high risk for fracture and to increase bone mass in men with osteoporosis at high risk for fracture. It is also approved for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for breast cancer, both at high risk for fracture. Stoboclo is a biosimilar, meaning it is highly similar to an already approved biologic drug, Prolia (denosumab). Stoboclo is also known by its drug name, denosumab-bmwo.

Stoboclo is a RANK ligand (RANKL) inhibitor. It works by blocking the RANKL protein, which plays a key role in the breakdown of bone. By inhibiting RANKL, Stoboclo helps to slow bone loss and increase bone strength, reducing the risk of fractures.

How do I take it?
Prescribing information states that Stoboclo is administered as a subcutaneous (under the skin) injection by a healthcare provider. The recommended dosing schedule is every six months, injected into the upper arm, upper thigh, or abdomen. People are often advised to take calcium and vitamin D supplements while receiving Stoboclo. The drug should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Stoboclo include back pain, musculoskeletal pain, pain in the extremities, hypercholesterolemia (high cholesterol), cystitis (bladder infection), arthralgia (joint pain), nasopharyngitis (common cold), hypertension (high blood pressure), bronchitis, and headache.

Rare but serious side effects may include severe hypocalcemia (low calcium levels in the blood), hypersensitivity with the risk of anaphylactic reactions (a severe immune system response that is potentially life-threatening), osteonecrosis of the jaw (bone tissue damage in the jaw), atypical femoral fractures (unusual thigh bone fractures), multiple vertebral fractures after treatment discontinuation, serious infections (such as cellulitis, a bacterial skin infection), severe dermatologic reactions (such as rashes or eczema), and severe bone, joint, or muscle pain.

For more information about this treatment, visit:

Stoboclo (Denosumab-Bmwo) Injection, for Subcutaneous Use — Celltrion